Skip to content


  • Poster presentation
  • Open Access

Achieving consensus over the assessment of clinical signs in eczema trials

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 2,
  • 6,
  • 1,
  • 1 and
  • 1
Trials201516 (Suppl 1) :P19

  • Published:


  • Atopic Dermatitis
  • Core Outcome
  • Adequate Validity
  • Large Group Discussion
  • Consensus Methodology


Eczema (syn. atopic dermatitis, atopic eczema) is a chronic, itchy, skin disease that commonly starts in childhood. Over 500 randomised controlled trials of eczema treatment have been conducted, but a core outcome set is lacking, leading to inefficiency and waste.

The Harmonizing Outcome Measures for Eczema (HOME) initiative seeks to agree a core set of outcomes for future research, and has previously agreed key outcome domains: clinical signs, patient-reported symptoms, quality of life and long-term control.

Materials and methods

Two systematic reviews were conducted as per the HOME methodology: i) review of outcome measures used to capture clinical signs, and ii) review of validation studies of the identified scales. Results of these reviews and other data were presented at a face-to-face consensus meeting.

The principle focus of the HOME III meeting, (April 2013, San Diego, USA), was to achieve consensus over the measurement of eczema clinical signs. The meeting included 56 participants (clinicians, patients, researchers and industry representatives) from 10 countries including Asia, Europe, South America, and the US. Consensus methodologies included: presentation of evidence, small and large group discussion and anonymous key-pad voting with pre-defined consensus criteria.


Of the 16 identified scales that assess eczema clinical signs, the Eczema Area and Severity Index (EASI) and the Scoring Atopic Dermatitis index (SCORAD) were identified as valid and reliable. The EASI has adequate validity, responsiveness, internal consistency, and intra-observer reliability. The SCORAD has adequate validity, responsiveness, inter-observer reliability, but unclear intra-observer reliability. HOME III delegates agreed that EASI was the preferred instrument to measure the core outcome of eczema signs in future AE-trials (90% of delegates in favour of EASI).


Those involved in designing, reporting and using evidence from clinical trials on eczema are asked to comply with this consensus to enable better evidence-based decision making and improved patient care.

Authors’ Affiliations

Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, NG9 2NR, UK
Centre for Evidence-based healthcare, Medical Faculty Carl Gustav Carus, TU Dresden, Germany
Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Department of Dermatology, Oregon Health & Sciences University, Portland, Oregon, USA
Department of Dermatology, Kyushu University, Fukuoka, Japan
Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Germany


© Thomas et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.